LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

LLY

908.52

+0.64%↑

UNH

593.89

-0.49%↓

NVO

131.93

+0.67%↑

JNJ

166.62

+1.37%↑

ABBV

196.25

+1.59%↑

Inicio・Lista de Acciones・ADMA Biologics Inc

ADMA Biologics Inc

Cerrado

Sector Salud

18.39 13.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

16.26

Máximo

19.29

Métricas clave
By Trading Economics
Ingresos	35M 18M
Ventas	8M 82M
BPA	0.08
Margen de beneficio	21.748
Empleados	624
EBITDA	7.9M 24M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+18.88 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-163M 4B
Apertura anterior	5.29
Cierre anterior	18.39

Noticias sobre sentimiento de mercado

By Acuity

50%

100 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

16.06 / 17.46 Soporte y Resistencia

ADMA Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2024, 23:42 UTC

Ganancias

Syrah Resources: Vidalia AAM Facility Has Ramped Up Operations

8 sept 2024, 23:41 UTC

Ganancias

Syrah Resources: No Natural Graphite Shipments in Half-Year to Chinese Anode Customers Amid Competition, Oversupply

8 sept 2024, 23:40 UTC

Ganancias

Syrah Resources: Half-Year Balama Production and Sales Decreased Compared With Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Revenue US$19 Mln Vs US$28.4 Mln in Prior Period

8 sept 2024, 23:37 UTC

Ganancias

Syrah Resources: Half-Year Comprehensive Loss US$63.3 Mln Vs US$37.1 Mln Loss in Prior Period

8 sept 2024, 22:38 UTC

Principales Noticias

Stocks Are Poised to Fall -- Barrons.com

8 sept 2024, 18:40 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- Update

8 sept 2024, 15:24 UTC

Principales Noticias

Boeing Reaches Deal With Biggest Union in Effort to Avoid Strike -- WSJ

8 sept 2024, 13:00 UTC

Principales Noticias

Crypto Plan Creates Potential Conflicts for Trump -- WSJ

8 sept 2024, 09:00 UTC

Principales Noticias

Nvidia Draws Antitrust Scrutiny as Enforcers Signal Early Interest in AI -- WSJ

8 sept 2024, 07:30 UTC

Principales Noticias

Biotechs Are in Focus as Congress Looks to Get Tougher on China -- Barrons.com

8 sept 2024, 01:00 UTC

Principales Noticias

Elon Musk's xAI Has Discussed Deal for Share in Future Tesla Revenue, Sources Say -- WSJ

7 sept 2024, 17:35 UTC

Principales Noticias

Fed Outlook Remains Uncertain After September Cut -- Barrons.com

7 sept 2024, 09:30 UTC

Principales Noticias

Jobs Slowdown Frustrates Investors Who Wanted Certainty on the Fed -- Heard on the Street -- WSJ

7 sept 2024, 08:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 sept 2024, 04:05 UTC

Principales Noticias

China's Forex Reserves Rose in August as U.S. Dollar Weakened -- WSJ

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

Comparación entre iguales

Cambio de precio

ADMA Biologics Inc Esperado

Precio Objetivo

By TipRanks

18.88% repunte

Estimación a 12 meses

Media 19.33 USD 18.88%

Máximo 20 USD

Mínimo 18 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ADMA Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para ADMA Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

16.06 / 17.46Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

100 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.